Results 11 to 20 of about 4,127 (170)

Transarterial radioembolization for hepatocellular carcinoma: a review

Journal of Hepatocellular Carcinoma, 2016
Rodolfo Sacco,1 Caterina Conte,2 Emanuele Tumino,1 Giuseppe Parisi,1 Sara Marceglia,3 Salvatore Metrangolo,1 Roberto Eggenhoffner,4 Giampaolo Bresci,1 Giuseppe Cabibbo,5 Luca Giacomelli4 1Department of Gastroenterology, Cisanello Hospital, Pisa ...
Sacco R, Conte C, Tumino E, Parisi G, Marceglia S, Metrangolo S, Eggenhoffner R, Bresci G, Cabibbo G, Giacomelli L   +9 more
doaj   +7 more sources

Combining Immunotherapy with Transarterial Radioembolization. [PDF]

Indian J Nucl Med, 2023
Hepatocellular carcinoma (HCC) has a high mortality rate due to the diagnosis of patients at advanced stages and ineffective systemic therapies. Immunotherapy is considered a new treatment option for unresectable HCC alternatives to the limitations of conventional cytotoxic chemotherapy. In this case report, we
Balaban Genc ZC, Soydemır E, Ersoy SA, Ones T.   +3 more
europepmc   +6 more sources

Transarterial Radioembolization: Overview of Radioembolic Devices. [PDF]

Semin Intervent Radiol, 2023
Serhal M, Gordon AC, Brown DB, Toskich BB, Lewandowski RJ.   +4 more
europepmc   +3 more sources

Understanding Current Trends and Advances in Transarterial Radioembolization Dosimetry. [PDF]

Diagnostics (Basel)
Transarterial radioembolization (TARE) is an established therapy for primary and secondary hepatic malignancies. Outcomes depend heavily on dosimetry, which has evolved from empirical and body-surface-area methods to partition and voxel-based approaches.
Young S, Naser-Tavakolian K, Sajan A, Reis S, Woodhead G, Sandow T, Gimenez J, Garcia-Reyes K, Berman Z, Krishnasamy VP.   +9 more
europepmc   +3 more sources

Transarterial radioembolization for liver tumors as neoadjuvant therapy: three case reports

Einstein (São Paulo), 2020
Transarterial radioembolization (TARE) with yttrium-90 microspheres is a palliative locoregional treatment, minimally invasive for liver tumors. The neoadjuvant aim of this treatment is still controversial, however, selected cases with lesions initially ...
Vithor de Oliveira Carvalho, Francisco Leonardo Galastri, Breno Boueri Affonso, Priscila Mina Falsarella, Leonardo Guedes Moreira Valle, Ben-Hur Ferraz-Neto, Marcelo Bruno de Rezende, Joaquim Maurício da Motta-Leal-Filho, Rodrigo Gobbo Garcia, Felipe Nasser   +9 more
doaj   +2 more sources

The Incidence of Ischemic Cholecystitis after Prophylactic Cystic Artery Embolization: A Single-Center Retrospective Study

The Arab Journal of Interventional Radiology, 2023
Background Prophylactic cystic artery embolization (CAE) is used to prevent radiation cholecystitis in patients undergoing transarterial radioembolization (TARE), but the incidence of ischemic cholecystitis following CAE remains unclear.
Benjamin J. Walker, Michael Lung, Hanin Lataifeh, Aditi Patel, Ibrahim Abukhiran, Mohammad Amarneh   +5 more
doaj   +1 more source

Standards of Practice in Transarterial Radioembolization [PDF]

CardioVascular and Interventional Radiology, 2013
Complications (minor/major) A minor complication is a treatment-related adverse event requiring no or minimal therapy with or without overnight hospitalization for observation. A major complication is a treatment-related adverse event requiring further therapy, increased level of care, or prolonged hospitalization [11].
Mahnken, Andreas H., Spreafico, Carlo, Maleux, Geert, Helmberger, Thomas, Jakobs, Tobias F.   +4 more
openaire   +3 more sources

[Preface to the Special Issue on Transarterial Radioembolization for Hepatocellular Carcinoma]. [PDF]

J Korean Soc Radiol
Kim HC.
europepmc   +3 more sources

Transarterial Radioembolization for Management of Hepatocellular Carcinoma. [PDF]

Oncologist, 2023
Abstract Transarterial radioembolization (TARE) with Yttrium-90 (Y90) is a growing area of study due to its benefits in early-, intermediate-, and late-stage hepatocellular carcinoma. Treatment intent, including curative therapy, bridging to transplant, and downstaging disease, informs treatment approach and dosimetry goals.
Badar W, Yu Q, Patel M, Ahmed O.
europepmc   +3 more sources

Retrospective SPECT/CT dosimetry following transarterial radioembolization [PDF]

Journal of Applied Clinical Medical Physics, 2020
AbstractTransarterial radioembolization (TARE) effectively treats unresectable primary and metastatic liver tumors through intra‐arterial injection of Yttrium‐90 (90Y) beta particle emitting microspheres which implant around the tumor. Current dosimetry models are highly simplistic and there is a large need for an image‐based dosimetry post‐TARE, which
Briana C. Thompson, William A. Dezarn
openaire   +3 more sources